Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti‐MDR1 ribozymes
Matthes Huesker, Yvonne Folmer, Michaela Schneider, Christine Fulda, Hubert E. Blum, Peter Hafkemeyer – 30 December 2003 – Human cancers, including hepatocellular carcinoma (HCC), are characterized by a high degree of drug resistance. The multidrug resistance (MDR) transporters MDR1‐P‐glycoprotein and MRP2 (multidrug‐associated protein 2) are expressed in almost 50% of human cancers, including HCCs. In this study, we analyzed the effect of anti‐MDR1 ribozymes, especially AFP promoter‐driven anti‐MDR1 ribozymes, to specifically chemosensitize HCC cells.